Loading clinical trials...
Loading clinical trials...
A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141
Conditions
Interventions
Bendamustine
Doxorubicin
+3 more
Locations
7
United States
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
IU Health Central Indiana Cancer Centers
Indianapolis, Indiana, United States
Community Regional Cancer Center
Indianapolis, Indiana, United States
IU Health Arnett Cancer Center
Lafayette, Indiana, United States
Metro Health Cancer Care
Wyoming, Michigan, United States
University of Rochester Medical Center
Rochester, New York, United States
Start Date
July 1, 2010
Primary Completion Date
December 1, 2017
Completion Date
December 1, 2017
Last Updated
October 6, 2023
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Sherif Farag, MB, BS
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions